Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 475

Sort by

Sort Order Select

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Blood blood.2024027287.

https://doi.org/10.1182/blood.2024027287

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2025) 145 (11): 1126–1135.

https://doi.org/10.1182/blood.2024025464

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT

Blood blood.2024025131.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Blood (2025) 145 (2): 234–243.

https://doi.org/10.1182/blood.2024026186

Published: 2025

Includes: Supplemental data

Journal Articles

An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Gianluca Asti, Saverio D'Amico, Luciana Carota, Davide Piscia, Francesco Casadei, Nono Saha Cyrille Merleau, Patricia Alonso de Apellániz, Anne Sophie Kubasch, Silke Gloaguen, Nicole Modler, Catalina Gonzalez Martin, Cesare Rollo, Juan Parras, Mattia Delleani, Elena Zazzetti, Elisabetta Sauta, Nico Curti, Nicolas Riccardo Derus, Gianluca Carlini, Daniele Dall'Olio, Claudia Sala, Lorenzo Dall'Olio, Luca Lanino, Giulia Maggioni, Alessia Campagna, Marilena Bicchieri, Arturo Bonometti, Cesare Lancellotti, Daoud Rahal, Luca Di Tommaso, Tiziana Sanavia, Piero Fariselli, Matteo Zampini, Matteo Brindisi, Victor Savevski, Uwe Platzbecker, Maria Diez-Campelo, Lin Pierre Zhao, Pierre Fenaux, Torsten Haferlach, Vincent Planat, Raffaella Colombatti, Maria del Mar Mañú-Pereira, Anders Krogh, Silvia Uribe, Santiago Zazo, Enrico Giampieri, Gastone Castellani, Matteo Giovanni Della Porta, Federico Alvarez

Blood (2024) 144 (Supplement 1): 4989.

https://doi.org/10.1182/blood-2024-205541

Published: 2024

Journal Articles

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Jule Ussmann, Clara Wall, Lara Bischof, Jacob Jendro, Dominic Brauer, Donata Backhaus, Klaus H Metzeler, Marco Herling, Carmen Herling, Vladan Vucinic, Georg-Nikolaus Franke, Maximilian Merz, Timm Denecke, Uwe Platzbecker, Sebastian Schwind, Hans-Jonas Meyer, Madlen Jentzsch

Blood (2024) 144 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2024-199943

Published: 2024

Journal Articles

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Vladan Vucinic, David Fandrei, Janine Kirchberg, Enrica Bach, Mandy Brueckner, Kathleen Friedrich, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Simone Heyn, Uwe Platzbecker, Maximilian Merz

Blood (2024) 144 (Supplement 1): 2094.

https://doi.org/10.1182/blood-2024-207117

Published: 2024

Journal Articles

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

Blood (2024) 144 (Supplement 1): 4981.

https://doi.org/10.1182/blood-2024-209541

Published: 2024

Journal Articles

Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2024-206248

Published: 2024

Journal Articles

Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways

Maroof Hasan, Shahid Tannu, Shikha Saini, Manuel Ugidos, Guillermo Garcia-Manero, Uwe Platzbecker, Ching-Pin Chang, Anita K. Gandhi, Ricardo Garcia, Rajasekhar N.V.S. Suragani

Blood (2024) 144 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2024-194241

Published: 2024

Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 3228.1.

https://doi.org/10.1182/blood-2024-200797

Published: 2024

Journal Articles

Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)

Marie Sebert, Uwe Platzbecker, David Valcarcel Ferreiras, Valeria Santini, Uma Borate, Stephanie M. Kapsalis, Lorene Simonot, Weishi Yuan, Prapti A. Patel, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 1845.1.

https://doi.org/10.1182/blood-2024-198172

Published: 2024

Journal Articles

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Blood (2024) 144 (Supplement 1): 666.

https://doi.org/10.1182/blood-2024-194405

Published: 2024

Journal Articles

Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium

Blood (2024) 144 (Supplement 1): 665.

https://doi.org/10.1182/blood-2024-200184

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)

Blood (2024) 144 (Supplement 1): 105.

https://doi.org/10.1182/blood-2024-205413

Published: 2024

Journal Articles

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 776.

https://doi.org/10.1182/blood-2024-204763

Published: 2024

Journal Articles

The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema

Blood (2024) 144 (Supplement 1): 404.

https://doi.org/10.1182/blood-2024-204633

Published: 2024

Journal Articles

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Arjan A. van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2024) 144 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2024-201374

Published: 2024

NARROW

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms

Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only